Astellas Pharma Past Earnings Performance
Past criteria checks 3/6
Astellas Pharma's earnings have been declining at an average annual rate of -31.6%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 6.5% per year. Astellas Pharma's return on equity is 3.6%, and it has net margins of 3.1%.
Key information
-31.6%
Earnings growth rate
-30.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 6.5% |
| Return on equity | 3.6% |
| Net Margin | 3.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Astellas Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,772,155 | 54,746 | 799,059 | 324,570 |
| 30 Jun 24 | 1,701,806 | 21,519 | 775,191 | 316,416 |
| 31 Mar 24 | 1,603,672 | 17,045 | 740,110 | 294,187 |
| 31 Dec 23 | 1,543,324 | 4,198 | 706,256 | 286,410 |
| 30 Sep 23 | 1,523,572 | 38,090 | 669,778 | 278,898 |
| 30 Jun 23 | 1,511,818 | 107,031 | 645,058 | 266,713 |
| 31 Mar 23 | 1,518,619 | 98,714 | 630,272 | 276,128 |
| 31 Dec 22 | 1,468,235 | 136,430 | 613,397 | 274,414 |
| 30 Sep 22 | 1,406,682 | 148,911 | 586,290 | 266,127 |
| 30 Jun 22 | 1,351,811 | 118,211 | 565,127 | 261,704 |
| 31 Mar 22 | 1,296,163 | 124,086 | 548,840 | 246,010 |
| 31 Dec 21 | 1,300,914 | 120,167 | 547,692 | 233,316 |
| 30 Sep 21 | 1,285,714 | 119,360 | 532,687 | 231,849 |
| 30 Jun 21 | 1,268,702 | 100,863 | 520,649 | 225,514 |
| 31 Mar 21 | 1,249,528 | 120,589 | 504,316 | 224,489 |
| 31 Dec 20 | 1,253,215 | 138,307 | 508,764 | 233,293 |
| 30 Sep 20 | 1,265,853 | 139,722 | 515,363 | 230,952 |
| 30 Jun 20 | 1,273,678 | 187,306 | 502,601 | 228,007 |
| 31 Mar 20 | 1,300,843 | 195,411 | 499,295 | 224,226 |
| 31 Dec 19 | 1,289,855 | 220,751 | 488,054 | 218,477 |
| 30 Sep 19 | 1,309,722 | 246,925 | 484,800 | 214,090 |
| 30 Jun 19 | 1,311,397 | 226,224 | 494,845 | 210,057 |
| 31 Mar 19 | 1,306,348 | 222,265 | 490,263 | 208,682 |
| 31 Dec 18 | 1,305,901 | 213,600 | 484,099 | 209,117 |
| 30 Sep 18 | 1,307,658 | 186,429 | 481,546 | 212,867 |
| 30 Jun 18 | 1,306,830 | 176,770 | 478,883 | 216,436 |
| 31 Mar 18 | 1,300,316 | 164,679 | 478,330 | 220,781 |
| 31 Dec 17 | 1,305,521 | 182,515 | 484,126 | 221,463 |
| 30 Sep 17 | 1,299,746 | 185,754 | 478,249 | 215,938 |
| 30 Jun 17 | 1,296,484 | 194,556 | 471,227 | 213,584 |
| 31 Mar 17 | 1,311,665 | 218,701 | 470,777 | 208,129 |
| 31 Dec 16 | 1,312,627 | 207,940 | 474,335 | 208,958 |
| 30 Sep 16 | 1,336,878 | 205,818 | 481,460 | 213,295 |
| 30 Jun 16 | 1,366,799 | 215,678 | 493,582 | 220,707 |
| 31 Mar 16 | 1,372,706 | 193,687 | 500,359 | 225,665 |
| 31 Dec 15 | 1,360,153 | 185,659 | 497,984 | 223,590 |
| 30 Sep 15 | 1,340,307 | 168,805 | 490,493 | 221,608 |
| 30 Jun 15 | 1,295,761 | 144,617 | 474,276 | 214,931 |
| 31 Mar 15 | 1,247,259 | 135,856 | 452,522 | 206,594 |
| 31 Dec 14 | 1,205,276 | 124,154 | 251,755 | 339,460 |
| 30 Sep 14 | 1,177,660 | 112,663 | 296,063 | 288,487 |
| 30 Jun 14 | 1,159,218 | 104,614 | 343,246 | 239,103 |
| 31 Mar 14 | 1,139,909 | 90,874 | 397,018 | 191,460 |
| 31 Dec 13 | 1,137,824 | 79,679 | 433,675 | 181,955 |
Quality Earnings: YPHA has a large one-off loss of ¥103.9B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: YPHA's current net profit margins (3.1%) are higher than last year (2.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: YPHA's earnings have declined by 31.6% per year over the past 5 years.
Accelerating Growth: YPHA's earnings growth over the past year (43.7%) exceeds its 5-year average (-31.6% per year).
Earnings vs Industry: YPHA earnings growth over the past year (43.7%) exceeded the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: YPHA's Return on Equity (3.6%) is considered low.